11d agoSeeking AlphaBEARISH 32Product/PR
Alumis falls after mid-stage trial setback for lead drug
Alumis (ALMS) stock slides as a mid-stage trial for the company
Archived explainer. For the current picture see today's ALMS page.
Why Is ALUMIS INC EQUITY (ALMS) Stock Down Today?
By the Top Tier Newswire AI Desk · September 1, 2026 at 11:27 AM ET · reviewed against 9 wire stories
ALUMIS INC EQUITY (ALMS) is down -58.28% in the latest session. Our newswire has captured 9 stories on ALMS across 6 sources in the last 36 hours, with AI sentiment reading bearish (avg 36/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why ALMS stock is down today
ALMS stock is down 58.28% today, closing at $9.10, driven by the announcement that its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus failed to meet primary and secondary endpoints. The stock opened at $10.25, already down 53.0% from the prior close, and continued to fall throughout the session. The company filed an 8-K on September 1, 2026, disclosing the trial results and related events.
What Happened
Alumis Inc. reported that its Phase 2b LUMUS trial for envudeucitinib did not meet its primary or secondary endpoints. While a prespecified IFNGS-high subgroup showed some responses, the overall trial results were negative. This outcome led to a sharp sell-off in the stock and trading halts earlier in the day as news of the results was pending. The company’s lead drug candidate is now under greater scrutiny, and the market has reacted accordingly.
The stock’s intraday movement reflected the negative sentiment, with a high of $11.56 at 9:00 AM ET and a low of $9.05 at 11:25 AM ET. Trading volume surged to 11.7 million shares, significantly above the 3-month daily average of 1.2 million shares. The stock’s price has fallen sharply from its 52-week high of $31.35 to its current level of $9.10.
What The Data Shows
The stock has declined 55.3% over the last 8 sessions, from $22.86 to $10.23. Recent insider transactions also highlight concern among executives, with three officers selling shares on August 3, 2026. Over the past 90 days, insiders have sold a total of $534,000 worth of shares with no purchases recorded. The stock also printed 5 fresh 52-week lows on September 1, 2026, indicating continued pressure on the equity.
What To Watch
Investors should monitor the company’s next steps following the trial results. No upcoming earnings date was provided, but coverage breadth remains high with 9 stories from 6 sources in the last 36 hours. Any follow-up on the IFNGS-high subgroup or plans for future trials could influence the stock’s trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ALMS by the numbers
Last: $9.10Session: -58.28%7 sessions: -57.70%Coverage: 9 stories / 6 sourcesAI sentiment: 36/100 (bearish)Mkt cap: $2.9B52w: $3.76 to $31.35
The headlines behind the move
11d agoInvestorsHubBEARISH 28Product/PR
Alumis Phase 2b lupus trial misses primary and secondary endpoints
Alumis says its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus missed its overall endpoints, while a prespecified IFNGS-high subgroup showed responses.
11d agoThe FlyBEARISH 22General
Alumis falls -53.0%
12d agoInvesting.com MarketsBEARISH 32General
Why is Alumis stock collapsing today?
Why is Alumis stock collapsing today?
12d agoInvesting.com MarketsBEARISH 22Earnings
Alumis stock tumbles 55% after lupus drug trial misses goals
Alumis stock tumbles 55% after lupus drug trial misses goals
12d agoSEC 8-KNEUTRAL 50General
ALUMIS INC. (ALMS) files 8-K
Filed: 2026-09-01 AccNo: 0001104659-26-104145 Size: 11 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
12d agoThe FlyBEARISH 28Product/PR
Alumis reports LUMUS trial did not meet primary, secondary endpoints
12d agoThe FlyNEUTRAL 50General
Alumis trading halted, news pending
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ALMS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ALMS move explainers: 2026-09-03 · 2026-09-02 · 2026-09-01